{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:02:20Z","timestamp":1748059340664,"version":"3.41.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with hidradenitis suppurativa (HS) treated with tumour necrosis factor (TNF) inhibitors are at an increased risk for tuberculosis (TB) reactivation, necessitating baseline latent TB infection (LTBI) screening. However, evidence regarding the value of periodic LTBI screening in this population is limited. In this single-centre retrospective chart review, we investigated the LTBI rate in patients with HS treated with the TNF inhibitors adalimumab or infliximab. The cohort included 92 patients with a median treatment duration of 30\u2005months (range 3\u2013175) and a median interferon-gamma release assay number of 3 (range 1\u20138). The cumulative observation time was 286 person-years. Our investigation found no positive LTBI results in patients with HS on TNF inhibitors, challenging clinicians to reconsider the utility of serial screening for such patients who are otherwise at low risk for TB. Further research is essential for the development of evidence-based guidelines to optimize patient care and healthcare resource allocation.<\/jats:p>","DOI":"10.1093\/ced\/llaf014","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:01:11Z","timestamp":1737504071000},"page":"1193-1195","source":"Crossref","is-referenced-by-count":0,"title":["Tuberculosis screening in patients with hidradenitis suppurativa on tumour necrosis factor inhibitors: a\u00a0retrospective chart review"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-7125","authenticated-orcid":false,"given":"Katherine G","family":"Byrnes","sequence":"first","affiliation":[{"name":"University of Virginia School of Medicine , Charlottesville, VA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2025052303171182800_llaf014-B1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2011.09.007","article-title":"Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting","volume":"66","author":"Kardos","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025052303171182800_llaf014-B2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2022.05.027","article-title":"Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center, retrospective cohort study","volume":"87","author":"Khanna","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025052303171182800_llaf014-B3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2020.01.012","article-title":"Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025052303171182800_llaf014-B4","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jaad.2020.03.039","article-title":"Reply to: \u201cEvidence-based guidelines for tuberculosis screening before biologic treatment initiation\u201d","volume":"83","author":"Fernandez","year":"2020","journal-title":"J Am Acad Dermatol"},{"author":"CDC","key":"2025052303171182800_llaf014-B5","article-title":"Tuberculosis (TB). Reported tuberculosis in the United States, 2022"},{"key":"2025052303171182800_llaf014-B6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2024.02.051","article-title":"Annual tuberculosis screening in patients on biologics has questionable value","volume":"92","author":"Kist","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf014\/61531262\/llaf014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1193\/61531262\/llaf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1193\/61531262\/llaf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:17:20Z","timestamp":1747984640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/6\/1193\/7965951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":6,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,22]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf014","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,22]]}}}